AlphAIAlphAI — Financial news for AI agents
yahoo.comAUG 193 min read$HROW

Harrow (HROW) Q2 2026 Earnings Call Transcript

Harrow (HROW) reported Q2 2026 revenue of $70.7M, up 11% YoY, with first-half revenue at $115M. Key products IHEEZO and VEVYE showed growth, with IHEEZO achieving record unit demand and VEVYE seeing a 21% sequential prescription increase. The company expects stronger revenue and profitability in the second half, driven by improved product economics, broader commercial coverage, and strategic acquisitions like TYRVAYA. Harrow reiterated its full-year guidance, anticipating sequential revenue grow

Original reporting
yahoo.com
Published Aug 19, 2026, 10:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 10:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Harrow (HROW) Q2 2026 Earnings Call Transcript — source image
Source · yahoo.com
Decision brief

The 30-second read

$HROWBullishMed
01

Why it matters

The earnings beat and forward guidance suggest accelerating revenue growth in HROW's pipeline.

02

Market read

First‑time earnings disclosure for HROW with better‑than‑expected results and upbeat outlook, offering a short‑term trading opportunity.

03

What to watch

Execution risk on new product launches and acquisition integration.

Relevance 6/10Novelty 7/10Timing: post‑earnings release

Background

Harrow (HROW) is a specialty ophthalmic company focusing on dry‑eye treatments.

Company-level read

Ticker impact

$HROWBullishHigh confidence
Context

Harrow reported Q2 2026 revenue of $70.7M, up 11% YoY, and provided guidance for the second half of 2026.

Expected impact

Potential modest price gain in the next few trading days.

Evidence & confidence

First‑time disclosure of earnings and guidance for a small‑cap biotech; numbers exceed prior expectations.

Market effects

Sector

May lift other dry‑eye and ophthalmology stocks as Harrow's growth drivers are highlighted.

Regional

Limited to US biotech sector.

Global

Low; primarily a US‑focused micro‑cap event.

Counterpoint

What could challenge this read

If the guidance is overly optimistic, the stock could be vulnerable to a pull‑back on later quarters.

Key entities

  • Executive
    Mark L. Baum

    CEO delivering the earnings call.

  • Executive
    Andrew Boll

    CFO presenting financial details.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 21
$HROWMedAI 8/10

What's Going On With Harrow Stock Friday? - Harrow (NASDAQ:HROW)

Harrow Inc. (NASDAQ:HROW) reported positive results from a clinical study of its ocular anesthetic IHEEZO, showing significant pain reduction compared to a control. Analysts noted the findings support long-term growth and maintained an Outperform rating. HROW shares were down 1.33% at $41.50 on Friday.

benzinga.com2 min
AUG 20
$HROWMed

Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target

Harrow Inc. (HROW) reported H1 2026 revenue of $115M, below expectations, but reaffirmed its full-year guidance of $350M-$365M. Key products IHEEZO, VEVYE, and TRIESENCE showed strong growth, but the company faces a steep H2 revenue target. Harrow also announced a pending deal for TYRVAYA, expected to add $30M in 2027 revenue. Adjusted EBITDA was negative $1.2M for the quarter, and the company has $83.9M in cash.

yahoo.com2 min